Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Gets NY State Approval for Tumor Test

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that the New York State Department of Health has granted the firm approval to begin processing patient samples from the state for its miRview mets^2 test.

New York requires providers of laboratory-developed tests to receive approval from the state to process samples from patients within the state. It's the only state in the union to require that independent regulatory review process.

Rosetta's miRview mets^2 test is a microRNA-based assay that identifies the primary origin of tumors that have an uncertain unknown origin. It offers a panel of 42 identifiable tumor origins. In a study of 509 samples the test provided an accurate result in 85 percent of the samples, and in 82 percent of the cases a single tissue of origin prediction was given with an accuracy of 90 percent, said Rehovot, Israel-based Rosetta.

"With approximately 200,000 cases of cancer of unknown primary (CUP) and difficult to diagnose metastatic cancer per year in the US, there is a pressing clinical need for more accurate identification of the tumor of origin," Kenneth Berlin, president and CEO of Rosetta Genomics, said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.